Zai Lab's future trajectory hit a high note back in 2024 when the FDA approved COBENFY™, their promising treatment for schizophrenia. Morgan Stanley came out swinging, rating Zai Lab as Overweight with a price target of $50 per share, underscoring confidence after this significant milestone. But let's break down why this matters beyond just the buzz.
COBENFY™: A Game Changer or Just Hype?
Now, here’s where it gets juicy: Zai Lab secured the rights to COBENFY™, known scientifically as xanomeline/trospium chloride or